Pancreatic Cancer: A Review.

Pancreatic cancer is now the third leading cause of cancer related deaths in the United States, yet advances in treatment options have been minimal over the past decade. In this review, we summarize the evaluation and treatments for this disease. We highlight molecular advances that hopefully will soon translate into improved outcomes.

[1]  I. Rigoutsos,et al.  HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer , 2013, RNA biology.

[2]  M. Gönen,et al.  Prognostic Significance of Pathologic Nodal Status in Patients with Resected Pancreatic Cancer , 2007, Journal of Gastrointestinal Surgery.

[3]  L. Qin,et al.  A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers , 2012, PloS one.

[4]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[5]  D. Silverman,et al.  Occupational risk factors and pancreatic cancer: A review of recent findings , 2012, Molecular carcinogenesis.

[6]  C. Schmoor,et al.  Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer , 2012, British Journal of Cancer.

[7]  Jeffrey E. Lee,et al.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Zhe Zhang,et al.  Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. , 2012, Gastroenterology.

[9]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[10]  R. Hruban,et al.  Familial Pancreatic Cancer , 2008 .

[11]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[12]  Laura H. Tang,et al.  Failure Patterns in Resected Pancreas Adenocarcinoma: Lack of Predicted Benefit to SMAD4 Expression , 2013, Annals of surgery.

[13]  Geoffrey S. Tobias,et al.  Family history of cancer and risk of pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan) , 2010, International journal of cancer.

[14]  K. Lillemoe,et al.  Long-Term Outcomes and Prognostic Factors for Patients With Unresectable Locally Advanced Pancreatic Cancer Treated With Intraoperative Radiotherapy at the Massachusetts General Hospital , 1978 to 2010 , 2013 .

[15]  T. Mitsudomi,et al.  Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation , 2010, Cancer and Metastasis Reviews.

[16]  Jun Liu,et al.  Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. , 2011, European journal of cancer.

[17]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[18]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Baylin,et al.  Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer , 2008, Clinical Cancer Research.

[20]  T. Conroy,et al.  Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P Boffetta,et al.  Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  E. Van Cutsem,et al.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Ying,et al.  Familial risk of pancreatic cancer. , 2001, Journal of the National Cancer Institute.

[24]  D. Silverman,et al.  Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Saga,et al.  Relation of pancreatic duct hyperplasia to carcinoma , 1979, Cancer.

[26]  Alison P. Klein,et al.  Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds , 2004, Cancer Research.

[27]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[28]  M. Woodward,et al.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.

[29]  Jeffrey E. Lee,et al.  Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators , 2012, Cancer.

[30]  A. Klein.  Genetic susceptibility to pancreatic cancer , 2012, Molecular carcinogenesis.

[31]  T. Conroy,et al.  Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial , 2007 .

[32]  Abe Fingerhut,et al.  Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. , 2007, Surgery.

[33]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[34]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[35]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[36]  A. Basu,et al.  New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. , 2009, The Lancet. Oncology.

[37]  Sara Gandini,et al.  Tobacco and the risk of pancreatic cancer: a review and meta-analysis , 2008, Langenbeck's Archives of Surgery.

[38]  A. Gemma,et al.  F1000 highlights , 2010 .

[39]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Jeffrey E. Lee,et al.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. , 2008, Journal of the American College of Surgeons.

[42]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[43]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[44]  A. Maitra,et al.  Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[46]  M. Kendrick.  Laparoscopic and robotic resection for pancreatic cancer. , 2012, Cancer journal.

[47]  B. Erickson,et al.  Borderline Resectable Pancreatic Cancer: Definitions and the Importance of Multimodality Therapy , 2010, Annals of Surgical Oncology.

[48]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[49]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[50]  J. Neoptolemos,et al.  Postoperative pancreatic fistula: an international study group (ISGPF) definition. , 2005, Surgery.

[51]  M. Tsao,et al.  Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer , 2010, Cancer.

[52]  Paul Fockens,et al.  International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer , 2012, Gut.

[53]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[54]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[55]  R. Abrams,et al.  Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial , 2011, Annals of Surgical Oncology.

[56]  J. Goodwin,et al.  Pancreatic cancer in the general population: Improvements in survival over the last decade , 2006, Journal of Gastrointestinal Surgery.

[57]  K. Campbell,et al.  Periampullary and Pancreatic Incidentaloma: A Single Institution's Experience With an Increasingly Common Diagnosis , 2006, Annals of surgery.

[58]  Manal M. Hassan,et al.  Diabetes and risk of pancreatic cancer: a pooled analysis of three large case–control studies , 2011, Cancer Causes & Control.

[59]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[60]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[61]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[62]  L. Koniaris,et al.  Preoperative Imaging for Resectable Periampullary Cancer: Clinicopathologic Implications of Reported Radiographic Findings , 2013, Journal of Gastrointestinal Surgery.

[63]  A. Maitra,et al.  Genetics and pathology of pancreatic cancer. , 2006, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[64]  Pek-Lan Khong,et al.  Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. , 2009, Radiology.

[65]  Peter Neuhaus,et al.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.

[66]  K. Lillemoe,et al.  Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (⩽20-mm Invasive Component): A Multi-institutional Analysis , 2016, Annals of surgery.

[67]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[68]  K. Lillemoe,et al.  Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer , 1999, British Journal of Cancer.

[69]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  D. Gouma,et al.  Toward improving uniformity and standardization in the reporting of pancreatic anastomoses: a new classification system by the International Study Group of Pancreatic Surgery (ISGPS). , 2010, Surgery.

[71]  R. Hruban,et al.  Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. , 2000, Cancer research.

[72]  R. Abrams,et al.  Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  A. Miller,et al.  Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  P. Bracci.  Obesity and pancreatic cancer: Overview of epidemiologic evidence and biologic mechanisms , 2012, Molecular carcinogenesis.

[75]  K. Horton,et al.  Pancreatic surgery for the radiologist, 2011: an illustrated review of classic and newer surgical techniques for pancreatic tumor resection. , 2011, AJR. American journal of roentgenology.

[76]  D. Gouma,et al.  Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). , 2007, Surgery.

[77]  Laura H. Tang,et al.  Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades , 2011, Annals of Surgical Oncology.

[78]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[79]  Michael A. Choti,et al.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.